
Donald R Vandevanter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5137475/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.	13.7	971
2	Decade-long bacterial community dynamics in cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5809-5814.	3.3	543
3	CFTR modulator theratyping: Current status, gaps and future directions. Journal of Cystic Fibrosis, 2019, 18, 22-34.	0.3	208
4	Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatric Pulmonology, 2004, 38, 314-320.	1.0	116
5	Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. Journal of Cystic Fibrosis, 2016, 15, 147-157.	0.3	108
6	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatric Pulmonology, 2013, 48, 666-673.	1.0	99
7	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 405-411.	0.3	96
8	Anti-PcrV antibody in cystic fibrosis: A novel approach targeting <i>Pseudomonas aeruginosa</i> airway infection. Pediatric Pulmonology, 2014, 49, 650-658.	1.0	90
9	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2019, 18, 236-243.	0.3	84
10	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. Journal of Cystic Fibrosis, 2017, 16, 600-606.	0.3	76
11	Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS ONE, 2018, 13, e0194060.	1.1	76
12	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2017, 16, 592-599.	0.3	69
13	Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, 696-704.	0.3	66
14	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.3	62
15	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	2.9	62
16	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.3	59
17	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology, 2010, 45, 1167-1172.	1.0	58
18	Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respiratory Research, 2010, 11, 137.	1.4	53

#	Article	IF	CITATIONS
19	Characterizing aggressiveness and predicting future progression of CF lung disease. Journal of Cystic Fibrosis, 2009, 8, S15-S19.	0.3	52
20	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 485-493.	1.5	52
21	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 720-726.	0.3	51
22	How much doPseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. Pediatric Pulmonology, 2005, 39, 504-506.	1.0	50
23	Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review. Medical Devices: Evidence and Research, 2011, 4, 179.	0.4	50
24	Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). Journal of Cystic Fibrosis, 2020, 19, 595-601.	0.3	49
25	Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens. Journal of Clinical Microbiology, 2016, 54, 613-619.	1.8	48
26	Clinical applications of pulmonary delivery of antibiotics. Advanced Drug Delivery Reviews, 2015, 85, 1-6.	6.6	46
27	A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1295-1305.	2.5	45
28	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. Journal of Pediatrics, 2016, 169, 116-121.e2.	0.9	44
29	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site. Pediatric Pulmonology, 2015, 50, 431-440.	1.0	43
30	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemporary Clinical Trials, 2018, 64, 35-40.	0.8	42
31	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of Cystic Fibrosis, 2016, 15, 634-640.	0.3	40
32	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatric Pulmonology, 2010, 45, 1156-1166.	1.0	39
33	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2015, 14, 763-769.	0.3	38
34	IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 372-379.	0.3	35
35	Relationship of Antibiotic Treatment to Recovery after Acute FEV ₁ Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2017, 14, 937-942.	1.5	35
36	Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 783-790.	0.3	34

DONALD R VANDEVANTER

#	Article	IF	CITATIONS
37	Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Annals of the American Thoracic Society, 2019, 16, 534-539.	1.5	33
38	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society, 2018, 15, 225-233.	1.5	32
39	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. Clinical Investigation, 2012, 2, 163-175.	0.0	31
40	Trisomy 8 in primary esthesioneuroblastoma. Cancer Genetics and Cytogenetics, 1991, 57, 133-136.	1.0	30
41	Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability. Annals of the American Thoracic Society, 2019, 16, 1534-1542.	1.5	26
42	Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012. Journal of Pediatrics, 2014, 165, 1091-1097.e2.	0.9	24
43	Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. Journal of Cystic Fibrosis, 2015, 14, 370-375.	0.3	24
44	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.3	24
45	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.3	24
46	Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization. Genes Chromosomes and Cancer, 1994, 11, 141-145.	1.5	22
47	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatric Pulmonology, 2008, 43, 739-744.	1.0	21
48	Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respiratory Medicine, 2011, 105, S9-S17.	1.3	21
49	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric Pulmonology, 2020, 55, 828-834.	1.0	21
50	Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 365-372.	1.2	20
51	BMI fails to identify poor nutritional status in stunted children with CF. Journal of Cystic Fibrosis, 2017, 16, 158-160.	0.3	20
52	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. Pediatric Pulmonology, 2015, 50, 856-862.	1.0	19
53	Microbial diversity in the cystic fibrosis airways: where is thy sting?. Future Microbiology, 2012, 7, 801-803.	1.0	18
54	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005. Journal of Cystic Fibrosis, 2013, 12, 332-337.	0.3	18

DONALD R VANDEVANTER

#	Article	IF	CITATIONS
55	Finding the relevance of antimicrobial stewardship for cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 511-520.	0.3	18
56	CFTR modulators and pregnancy: Our work has only just begun. Journal of Cystic Fibrosis, 2016, 15, 6-7.	0.3	15
57	Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation. Journal of Cystic Fibrosis, 2017, 16, 496-498.	0.3	15
58	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respiratory Medicine, 2011, 105, S18-S23.	1.3	14
59	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.3	13
60	The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2019, 18, 851-856.	0.3	12
61	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric Pulmonology, 2021, 56, 823-836.	1.0	11
62	Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. Journal of Cystic Fibrosis, 2021, 20, 965-971.	0.3	11
63	Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. Journal of Cystic Fibrosis, 2021, 20, 39-45.	0.3	9
64	Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007–2009. Journal of Cystic Fibrosis, 2013, 12, 786-789.	0.3	8
65	Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies. Current Opinion in Pulmonary Medicine, 2017, 23, 530-535.	1.2	8
66	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. Annals of the American Thoracic Society, 2020, 17, 1590-1598.	1.5	8
67	Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping. Nucleic Acids Research, 1992, 20, 1148-1148.	6.5	7
68	Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 257-263.	0.3	7
69	Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. Journal of Cystic Fibrosis, 2021, 20, 36-38.	0.3	7
70	Management of chronic <i>Pseudomonas aeruginosa</i> infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiology, 2021, 16, 1087-1104.	1.0	7
71	In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 151-154.	0.6	6
72	Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. Pediatric Pulmonology, 2017, 52, 1013-1019.	1.0	6

DONALD R VANDEVANTER

#	Article	IF	CITATIONS
73	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatric Pulmonology, 2018, 53, 43-49.	1.0	6
74	Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis. Journal of Cystic Fibrosis, 2022, , .	0.3	6
75	Antipseudomonal treatment decisions during CF exacerbation management. Journal of Cystic Fibrosis, 2022, 21, 753-758.	0.3	4
76	Retracing changes in cystic fibrosis understanding and management over the past twenty years. Journal of Cystic Fibrosis, 2022, 21, 3-9.	0.3	3
77	Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies. Annals of the American Thoracic Society, 2016, 13, 1890-1893.	1.5	2
78	Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis, 2022, , .	0.3	2
79	Electrophoretic isolation of extrachromosomal DNA from tumor cells. Genes Chromosomes and Cancer, 1995, 12, 262-271.	1.5	1
80	The challenge of improving outcomes for patients with CF sinonasal disease. Journal of Cystic Fibrosis, 2014, 13, 361-362.	0.3	1
81	Efficacy measures for clinical trials: A review series. Journal of Cystic Fibrosis, 2016, 15, 415.	0.3	1
82	The challenges of maintaining momentum in CF drug development and approval - Commentary. Journal of Cystic Fibrosis, 2017, 16, 170-171.	0.3	1
83	The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis. Annals of the American Thoracic Society, 2019, 16, 819-820.	1.5	1
84	Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. European Respiratory Journal, 2020, 55, 2000105.	3.1	1
85	The march towards CFTR modulator access for all people with CF: The end of the beginning. Journal of Cystic Fibrosis, 2021, 20, 185-187.	0.3	1
86	First Bacterial Infection as an Alternative Clinical End Point for Regulatory Approval of Agents Targeting the Primary Cystic Fibrosis Defect. Journal of Pediatrics, 2005, 147, 332-334.	0.9	0
87	Anti-Infective Therapies in Cystic Fibrosis. Milestones in Drug Therapy, 2017, , 153-169.	0.1	0
88	Cystic fibrosis: definition, severity and impact of pulmonary exacerbations. , 0, , 25-37.		0

6